收稿日期: 2023-07-25
网络出版日期: 2024-01-08
基金资助
河南省医学科技攻关计划项目(LHGJ20200094)
Efficacy of chocolate balloon assisted drug⁃coated balloon angioplasty for the treatment of TASC Ⅱ type C/D femoropopliteal artery lesions
Received date: 2023-07-25
Online published: 2024-01-08
目的 评价巧克力球囊辅助药物涂层球囊（DCB）血管成形术治疗TASCⅡ C/D型股腘动脉病变的疗效及安全性。 方法 回顾性分析2021年1月至2022年10月在阜外华中心血管病医院接受巧克力球囊+DCB或普通球囊+DCB治疗的58例TASCⅡ C/D型股腘动脉病变患者的临床资料，分为观察组（巧克力球囊+DCB）27例和对照组（普通球囊+DCB）31例。比较两组术中夹层发生率及术后临床疗效。 结果 观察组和对照组的技术成功率分别为88.9%和80.6%，观察组术中血管夹层、限流性夹层的发生率和补救性支架植入率均明显低于对照组（P < 0.05）。术后两组患者临床症状均较术前明显改善，观察组12个月累积一期通畅率明显高于对照组（P < 0.05）。两组12个月累积免于临床驱动的靶病变血运重建率差异无统计学意义（P > 0.05）。 结论 巧克力球囊辅助DCB血管成形术治疗TASCⅡ C/D型股腘动脉病变安全有效，可有效降低术中夹层发生率及补救性支架植入率，近期疗效优于普通球囊+ DCB的治疗。
李攀峰 , 李晓健 , 牛浩 . 巧克力球囊辅助药物涂层球囊血管成形术治疗TASCⅡ C/D型股腘动脉病变的疗效分析[J]. 实用医学杂志, 2023 , 39(23) : 3111 -3115 . DOI: 10.3969/j.issn.1006-5725.2023.23.015
Objective To evaluate the efficacy and safety of chocolate balloon assisted drug-coated balloon （DCB） angioplasty for the treatment of TASC Ⅱ type C/D femoropopliteal artery lesions. Methods The clinical data of 58 patients with TASC Ⅱ type C/D femoropopliteal artery lesions treated with chocolate balloon +DCB or plain balloon+DCB at Fuwai Central China Cardiovascular Hospital from January 2021 to October 2022 were retrospectively analyzed. A total of 27 cases were assigned to the observation group （chocolate balloon + DCB）and 31 cases tothe control group （plain balloon + DCB）. The rate of dissection and the clinical outcomes between the two groups were compared. Results The technical success rates of the observation and control groups were 88.9% and 80.6%， respectively. The rates of dissection， flow-limiting dissection， and bailout stenting were significantly lower in the observation group than of the control group （all P < 0.05）. Postoperative clinical symptoms of patients in both groups improved significantly compared with the preoperative period. The 12-month cumulative primary patency rate of the observation group was significantly higher than that of the control group （P < 0.05）. There was no significant difference in the 12-month cumulative freedom from clinically driven-target lesion revascularization rate between the two groups （P > 0.05）. Conclusion Chocolate balloonassisted DCB angioplasty was safe and effective for TASC Ⅱ type C/D femoropopliteal artery lesions. It reduced the rates of dissection and bailout stenting， and had better near-term outcomes than plain balloon + DCB.
| 1 | LIN Y， LI W， LIU W， et al. Mid-term outcomes of endovascular treatment and risk factors for recurrence in patients with Trans-Atlantic-Inter-Society Ⅱ C/D femoropopliteal lesions［J］. Quant Imag Med Surg， 2021， 11（5）：2028-2039. |
| 2 | FARHAN S， ENZMANN F K， BJORKMAN P， et al. Revascularization strategies for patients with femoropopliteal peripheral artery disease［J］. J Am Coll Cardiol， 2023， 81（4）：358-370. |
| 3 | FUKASE T， DOHI T， KATO Y， et al. Long-term clinical outcomes and cause of death after endovascular treatment for femoropopliteal artery lesions［J］. J Cardiol， 2021， 77（4）：417-423. |
| 4 | LAIRD J R， YEO K K. The treatment of femoropopliteal in-stent restenosis： Back to the future［J］. J Am Coll Cardiol， 2012， 59（1）：24-25. |
| 5 | DAVAINE J M， AZEMA L， GUYOMARCH B， et al. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus （TASC） C and D femoropopliteal lesions （the STELLA "STEnting Long de L'Artèrefémoralesuperficielle" cohort）［J］. Eur J Vasc Endovasc， 2012， 44（4）：432-441. |
| 6 | LIN Y， TANG X， FU W， et al. Stent fractures after superficial femoral artery stenting： risk factors and impact on patency［J］. J Endovasc Ther， 2015， 22（3）：319-326. |
| 7 | SCHEINERT D， SCHEINERT S， SAX J， et al.Prevalence and clinical impact of stent fractures after femoropopliteal stenting［J］. J Am Coll Cardiol， 2005， 45（2）：312-315. |
| 8 | 中华医学会外科学分会血管外科学组.下肢动脉硬化闭塞症诊治指南［J］. 中华医学杂志， 2015， 95（24）：1883-1896. |
| 9 | 李跃，王兵，牛晓阳，等.药物涂层球囊在自体动静脉瘘狭窄治疗中的应用［J］. 实用医学杂志， 2023，39（6）：724-729. |
| 10 | 崔风强，陈江浩，王辉，等. Acotec药物涂层球囊治疗下肢动脉硬化闭塞症的临床效果［J］. 实用医学杂志， 2021，37（24）：3184-3187. |
| 11 | TEPE G， LAIRD J， SCHNEIDER P， et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease： 12-month results from the IN.PACT SFA randomized trial［J］. Circulation， 2015， 131（5）：495-502. |
| 12 | JIA X， ZHANG J， ZHUANG B， et al. Acotec drug-coated balloon catheter： randomized， multicenter， controlled clinical study in femoropopliteal arteries： evidence from the AcoArt I trial［J］. JACC Cardiovasc Interv， 2016， 9（18）：1941-1949. |
| 13 | SPILIOPOULOS S， KARAMITROS A， REPPAS L， et al. Novel balloon technologies to minimize dissection of peripheral angioplasty［J］. Expert Rev Med Devices， 2019， 16（7）：581-588. |
| 14 | MUSTAPHA J A， LANSKY A， SHISHEHBOR M， et al.A prospective， multi-center study of the chocolate balloon in femoropopliteal peripheral artery disease： The Chocolate BAR registry［J］. Catheter Cardiovasc Interv， 2018， 91（6）：1144-1148. |
| 15 | SHIRAI S， MORI S， YAMAGUCHI K， et al. Impact of Chocolate percutaneous transluminal angioplasty balloon on vessel preparation in drug-coated balloon angioplasty for femoropopliteal lesion［J］. CVIR Endovasc， 2022，5（1）：46. |
| 16 | SIRIGNANO P， MANSOUR W， D'ADAMO A， et al. Early experience with a new concept of angioplasty nitinol-constrained balloon catheter （Chocolate?） in severely claudicant patients［J］. Cardiovasc Interv Radiol， 2018， 41（3）：377-384. |
| 17 | IIDA O， TAKAHARA M， SOGA Y， et al. Shared and differential factors influencing restenosis following endovascular therapy between TASC （Trans-Atlantic Inter-Society Consensus） II class A to C and D lesions in the femoropopliteal artery［J］. JACC Cardiovasc Interv， 2014， 7（7）：792-798. |
| 18 | OKUNO S， IIDA O， SHIRAKI T， et al. Impact of calcification on clinical outcomes after endovascular therapy for superficial femoral artery disease： assessment using the peripheral artery calcification scoring system［J］. J Endovasc Ther， 2016， 23（5）：731-737. |
| 19 | WARD C， MENA-HURTADO C. Novel use of pillows and grooves： the Chocolate? PTA balloon catheter［J］. Endovasc Today， 2014，13：24-28. |
| 20 | FUJIHARA M， TAKAHARA M， SASAKI S， et al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease［J］. J Endovasc Ther， 2017， 24（3）：367-375. |
| 21 | KOBAYASHI N， HIRANO K， YAMAWAKI M， et al. Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease［J］. J VascSurg， 2018， 67（4）：1151-1158. |
| 22 | ORMISTON W， DYER-HARTNETT S， FERNANDO R， et al. An update on vessel preparation in lower limb arterial intervention［J］. CVIR Endovasc， 2020， 3（1）：86. |
| 23 | GIANNOPOULOS S， VOLTEAS P， VIRVILIS D. Specialty balloons for vessel preparation during infrainguinal endovascular revascularization procedures a review of literature［J］. Vasc Endovasc Surg， 2023， 57（6）：599-606. |
| 24 | ABURAHMA A F， ABURAHMA Z T， SCOTT G， et al. Clinical outcome of drug-coated balloon angioplasty in patients with femoropopliteal disease： A real-world single-center experience［J］. J Vasc Surg， 2019， 70（6）：1950-1959. |
| 25 | MORI S， TAKAHARA M， NAKAMA T， et al. Impact of calcification on clinical outcomes after drug-coated balloon angioplasty for superficial femoral artery disease： Assessment using the peripheral artery calcification scoring system［J］. Catheter Cardio Interv， 2023，101（5）：892-899. |
/
| 〈 |
|
〉 |